DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE by Novartis is components: dorzolamide hydrochloride and timolol maleate. Approved for elevated intraocular pressure (iop) in patients with open-angle glaucoma, ocular hypertension. First approved in 2008.
Drug data last refreshed 18h ago
components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve…
Worked on DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.